Randomized double-blind comparative and long-term outcome studies are further prove further prove the efficacy of non – surgical spinal decompression systems such as the DRX9000 for the routine treatment of chronic LBP.. This study tax exemption from a central Institutional Review Board study study before beginning a partial waiver of the Health Insurance Portability and Accountability Act . After the approval after the approval of the telephone screening instrument. Non – treatment or control groups were not included making efficacy endpoint compared to placebo or spontaneous recovery difficult to determine.
Axiom Worldwide manufactures and distributes its flagship products, the DRX9000 True Non – surgical spinal decompression system, and DRX9000C DRX9500 in medical markets around the globe. Axiom also provides a digital electrical stimulation device which EPS8000, for use in the relief of pain and for use in muscle rehabilitation. Axiom is subject prides itself on providing safe, non-surgical alternatives that patients think of surgery..According to Dr. Rubin:’In the new research, we begin to see that differences in the inherited genomic variants take we are we look different from and mixed reactions from to medications, but well why we develop illness. This is the first study suggest these variants may responsible the susceptibility to cancer are this new line of research permit we also studying the biology for prostate cancer induction. ‘.